Status: Recruiting
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Participants needed: 700
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Tarsus Pharmaceuticals, Inc.Updated: May 20, 2026Locations: 19
Eligibility criteria
Overtly healthy adult participants aged 18 to 70 years [+4]
Prior exposure to TP05 or any isooxazoline in the last 12 months [+7]